American Capital Management Inc. reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 19.4% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 147,800 shares of the medical research company's stock after selling 35,500 shares during the quarter. American Capital Management Inc. owned about 0.29% of Charles River Laboratories International worth $29,112,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the company. Boston Trust Walden Corp boosted its stake in Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company's stock valued at $41,381,000 after buying an additional 5,375 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Charles River Laboratories International by 99.8% in the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company's stock worth $1,435,000 after purchasing an additional 2,646 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Charles River Laboratories International by 135,175.0% in the 2nd quarter. Quest Partners LLC now owns 5,411 shares of the medical research company's stock worth $1,118,000 after purchasing an additional 5,407 shares in the last quarter. New England Research & Management Inc. acquired a new stake in Charles River Laboratories International during the second quarter valued at approximately $506,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after buying an additional 3,714 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.
Charles River Laboratories International Stock Down 0.3 %
CRL traded down $0.53 during trading on Friday, reaching $199.06. 287,759 shares of the stock traded hands, compared to its average volume of 780,522. The stock's 50-day simple moving average is $194.32 and its two-hundred day simple moving average is $204.75. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00. The stock has a market cap of $10.18 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 5.13 and a beta of 1.38.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the company earned $2.72 EPS. The firm's revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.
Charles River Laboratories International declared that its board has approved a stock buyback plan on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its shares are undervalued.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on CRL shares. Baird R W downgraded Charles River Laboratories International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 8th. Evercore ISI increased their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. downgraded Charles River Laboratories International from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their target price for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, The Goldman Sachs Group cut their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus target price of $214.38.
Read Our Latest Stock Report on Charles River Laboratories International
Insiders Place Their Bets
In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company's stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.30% of the company's stock.
About Charles River Laboratories International
(
Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Recommended Stories
![Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=CRL)
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.